Search results for Hemomalvt

Single infusion of Roctavian linked to fewer bleeds in hemophilia A

Roctavian (valoctocogene roxaparvovec-rvox) was associated with fewer bleeding episodes and less need for preventive treatment, or prophylaxis, in most adult men with severe hemoph...

Data show hemophilia bleeds can be successfully treated while on Hympavzi

In the large clinical trial that supported the 2024 approval of Hympavzi (marstacimab) for adults and children with hemophilia, use of the prophylactic injection therapy was found...

Most men with hem A bleed-free 5 years after 1 Roctavian dose

A single dose of the gene therapy Roctavian (valoctocogene roxaparvovec-rvox) continues to prevent bleeds and the need for preventive treatment (prophylaxis) for up to five years i...

Abstract No. LBA9 A Prospective Multicenter Single-Arm Study to Evaluate the Safety and Effectiveness of Embraceâ„¢ Hydr...

A prospective, single-arm, multicenter study to evaluate the safety and effectiveness of Embrace Hydrogel Embolic System (HES), for transcatheter embolization of peripheral arteria...

Hemlibra outperforms ITI in controlling bleeding in hemophilia A children

Preventive treatment with Hemlibra (emicizumab) is associated with better bleeding control and lower medication costs compared with immune tolerance induction, or ITI, among childr...

Confident protection from hemophilia A

The post Confident protection from hemophilia A appeared first on Hemophilia News Today.

What to do during a bleeding emergency with hemophilia

When you or someone you love has hemophilia, even what seems like a minor bleed can quickly become serious. Knowing how to recognize a bleeding emergency and what steps to take can...

Hympavzi now approved for more hemophilia patients in Europe

The European Commission has approved Hympavzi (marstacimab) to treat certain people with hemophilia A or hemophilia B who have inhibitors, the therapy’s maker, Pfizer, announced. H...

FX activator may help with bleeding control in hemophilia A and B: Trials

Bemiltenase alfa, an experimental factor X (FX) activator, helped with on-demand bleeding control for people with hemophilia A and B who had developed inhibitors against standard f...

Denecimig excels at reducing bleeds in hemophilia A patients: Study

Denecimig (Mim8) was significantly better than on-demand or standard preventive treatments at reducing bleeding episodes in people with hemophilia A, regardless of inhibitor status...

4 SAFETY AND EFFICACY OF HEMOSTATIC AGENTS IN PATIENTS WITH POST-SPHINCTEROTOMY OR POST-ENDOSCOPIC PAPILLECTOMY BLEEDING...

rAAV8 HMR-001 Boosts Liver Gene Therapy in Hemophilia

In a groundbreaking advancement for gene therapy, researchers have unveiled two novel bioengineered AAV8 vectors—HMR-001 and its codon-optimized counterpart HMR-001z—that demonstra...

Real-world study backs safety of Hemlibra for acquired hemophilia A

Hemlibra (emicizumab) alongside immunosuppressive therapy appears safe for use in acquired hemophilia A (AHA), according to initial results of a real-world study in Japan, the only...

Abstract No. LBA3 ▪ FEATURED ABSTRACT The VENOS-2 Early Feasibility Study: Six-Month Outcomes of the Velocity® Percut...

Each of the two FDA-approved systems used to create percutaneous arteriovenous fistulas (pAVFs) for hemodialysis successfully and safely create vascular access. Unfortunately, many...

Hemophilia bleed or pain? How to tell when pain needs attention

When you have hemophilia, any new aches or pains can be a cause for concern. Because bleeding can happen in joints, muscles, and soft tissues, changes such as pain, swelling, or ti...

Abstract No. LBA5 Clinical, functional, and quality of life outcomes through 90 days in the STORM-PE RCT for mechanical...

Pulmonary embolism (PE) treatment with mechanical thrombectomy (MT) can rapidly relieve RV overload and may lead to faster normalization of hemodynamics and functional status compa...